Teclistamab-daratumumab combination approved by US FDA
The combination of teclistamab and daratumumab was approved by the US Food and Drug Administration (FDA) for treating patients with relapsed/refractory multiple myeloma (RRMM) who have received at least one prior line of therapy. Based on data from the phase 3 MajesTEC-3 trial, this is the third approval under the new Commissioner’s National Priority Voucher (CNPV) pilot program. The accelerated approval for teclistamab monotherapy was concomitantly converted to a traditional approval. The combination is currently available only under a Risk Evaluation and Mitigation Strategy (REMS) program.

European experts publish guidance on teclistamab management for RRMM
The BCMA-targeted bispecific antibody teclistamab is recommended as a treatment option at second or subsequent relapse for patients with myeloma with disease refractory to/relapsing after treatment with all three major drug classes, including immunomodulatory drugs, proteasome inhibitors, and anti-CD38 monoclonal antibodies. A European panel of myeloma experts has published recommendations on managing patients receiving teclistamab in routine clinical practice. The guidance, published in Clinical Leukemia Lymphoma and Myeloma, outlines strategies for optimizing prophylaxis for cytokine release syndrome and infection, along with immunoglobulin replacement therapy and dosing approaches.

Real-world study confirms teclistamab efficacy in heavily pretreated RRMM
In the REALiTEC retrospective observational study, patients with heavily pretreated RRMM who received teclistamab monotherapy had a median overall survival of 26.3 months. In the study, published in Hematologica, most (78.8%) patients were triple-class refractory; 44.2% were penta-class refractory.

 Significant overall survival improvement seen with cilta-cel
The phase 3 CARTITUDE-4 trial shows a significant improvement in overall survival (OS) with ciltacabtagene autoleucel (cilta-cel) in patients with RRMM after one to three previous lines of therapy, compared with standard-of-care (SoC). In updated analyses, with a median follow-up of 30.9 months, the hazard ratio for the median OS comparison favored cilta-cel over SoC, translating to a 45% reduction in risk of death. These findings were reported in The Lancet Oncology.

Real-world NDMM outcomes are comparable to PERSEUS results
A retrospective analysis of real-world data showed that outcomes for patients with newly diagnosed myeloma who received daratumumab-bortezomib-lenalidomide-dexamethasone (Dara-VRd) and transplant at the Mayo Clinic Comprehensive Cancer Center were comparable to recipients of Dara-VRd and transplant in the phase 3 PERSEUS trial. The value of dual Dara-R maintenance, however, could not be clearly established, according to the analysis reported in Haematologica.